Triple-negative breast cancers (TNBCs), which is clinically defined by the absence of ER, progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2), accounts for about 15∼20% of all newly diagnosed breast cancer cases [12]. This evidence concerns the gene PGR and breast carcinoma.